突变体
生物
交易激励
DNA
抑制器
突变
血浆蛋白结合
细胞生物学
遗传学
转录因子
癌症
基因
作者
Alex N. Bullock,Julia Henckel,Alan R. Fersht
出处
期刊:Oncogene
[Springer Nature]
日期:2000-03-02
卷期号:19 (10): 1245-1256
被引量:384
标识
DOI:10.1038/sj.onc.1203434
摘要
The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37°C the wild-type protein has a stability of 3.0 kcal/mol. This also emerges as an oncogenic threshold: all β-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region. Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.
科研通智能强力驱动
Strongly Powered by AbleSci AI